Protocol ASPEN-09-03: A Single-arm Phase 2 Multicenter Study of Evorpacept in Combination With Trastuzumab and Chemotherapy in Participants With Metastatic HER2-Positive Breast Cancer, a Substudy Under Master Protocol ASPEN-09: A Phase 1b/2, Multicenter, Multi Arm Study of Evorpacept in Combination With Anti-cancer Therapies in Advanced / Metastatic Malignancies

This study is testing a new drug called evorpacept, combined with standard treatments, for people with HER2-positive breast cancer that has spread to other parts of the body. Researchers want to see if adding this new medicine helps the immune system better fight cancer cells that have stopped responding to previous therapies.

You may be eligible if you have HER2-positive breast cancer that has continued to grow or spread after you have already taken a treatment called T-DXd (Enhertu). Participants must also be in good enough general health to receive chemotherapy and have tumors that are measurable on medical scans.

If you join, you will receive evorpacept along with a combination of targeted therapy and a specific chemotherapy chosen by your medical team. Doctors will closely monitor your health and the size of your tumors throughout the study to see how well the treatment is working and if it is safe for you.

The study is currently open and recruiting new participants at specific medical centers in Tucson, Arizona, and Duarte and La Jolla, California. Your medical team can help determine if a site near you is participating.